🔍

SUMICHEM - Sumitomo Chemi.

📊 NSE: SUMICHEM 🏢 Pesticides / Agrochemicals - Indian 📅 Last Updated: 12/14/2025 13:48

📢 Recent Corporate Announcements

Sumitomo Chemical India to Meet Institutional Investors on February 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 02:46 PM

Sumitomo Chemical India Limited has scheduled a group meeting with institutional investors and analysts on February 26, 2026, in Mumbai. The interaction is organized by IIFL Capital Services Limited and is slated to begin at 10:00 A.M. The company has explicitly stated that discussions will be based on publicly available information and no unpublished price sensitive information will be shared. This is a routine engagement aimed at maintaining transparency with the investment community.

Group meeting with investors and analysts scheduled for February 26, 2026
Interaction organized by IIFL Capital Services Limited in Mumbai
Meeting to commence from 10:00 A.M. onwards
Compliance with Regulation 30(6) of SEBI (LODR) Regulations, 2015
Discussions restricted to publicly available information only

💡 No immediate action is required as this is a routine investor meeting. Investors should look out for any post-meeting presentations or transcripts for potential insights into the company's strategy.

Sumitomo Chemical Q3 Revenue Dips 12% to ₹568 Cr; Margins Expand to 47.4%

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 12:48 PM

Sumitomo Chemical India reported a 12% YoY decline in Q3FY26 revenue to ₹568 crore, largely due to the strategic discontinuation of the low-margin Animal Nutrition distribution business and soft domestic demand. Despite the revenue dip, gross margins expanded significantly by 522 bps to 47.4% through a superior product mix and disciplined pricing. Net profit fell 13% YoY to ₹75.8 crore, weighed down by a one-time exceptional charge of ₹16.1 crore related to newly notified Labour Codes. The company provided clarity on its ₹160 crore capex projects, with commercialization expected between Q4 FY28 and Q2 FY29.

Q3FY26 revenue fell 12% YoY to ₹568 crore, while 9MFY26 revenue grew 3% to ₹2,555 crore.
Gross margins improved to 47.4% in Q3 from 42.1% YoY, supported by the exit from the low-margin AND business (₹72 crore impact).
Net Profit for Q3 stood at ₹75.8 crore, impacted by a ₹16.1 crore one-time exceptional charge for Labour Code compliance.
Announced commercialization timelines for ₹150 crore Dahej project (Q2 FY29) and ₹10 crore Tarapur project (Q4 FY28).
Maintains a strong balance sheet with cash and cash equivalents of approximately ₹2,163 crore as of December 31, 2025.

💡 Investors should focus on the significant margin expansion and the company's transition toward high-margin patented molecules from its parent company. While short-term domestic demand remains soft, the strong cash position and upcoming capex provide a solid long-term growth outlook.

Sumitomo Chemical Q3 PAT Falls 13% to ₹76 Cr on One-time Charge; Margins Expand 522 bps

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 27 Jan 2026, 10:46 PM

Sumitomo Chemical India reported a 12% YoY decline in Q3FY26 revenue to ₹568 crore, largely due to the strategic discontinuation of the low-margin Animal Nutrition distribution business. Despite the revenue dip, gross margins expanded significantly by 522 bps to 47.4% due to a favorable product mix and disciplined pricing. Net profit fell 13% to ₹75.8 crore, primarily impacted by a one-time exceptional charge of ₹16.1 crore related to new Labour Code provisions. The company also announced a strategic ₹150 crore capex for its Dahej site to manufacture patented molecules for its Japanese parent company.

Q3 Revenue declined 12% YoY to ₹568 crore, impacted by a ₹72 crore revenue loss from discontinued low-margin business.
Gross Profit Margin improved to 47.4% from 42.1% YoY, while EBITDA margin rose to 17.5%.
Board approved ₹150 crore capex for a herbicide intermediate plant at Dahej for global supply to the parent company.
Net Profit of ₹75.8 crore was affected by a ₹16.1 crore one-time exceptional charge; excluding this, PBT remained stable.
Cash and cash equivalents stood at a robust ₹2,163 crore as of December 31, 2025.

💡 Investors should look past the headline PAT decline as it was driven by a one-time charge and the exit from low-margin segments. The significant margin expansion and the new capex for the parent company's patented molecules signal a positive long-term shift toward higher-value manufacturing.

Sumitomo Chemical India Files Q3 FY26 Results; Reports Zero Loan Defaults

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 27 Jan 2026, 02:08 PM

Sumitomo Chemical India Limited has submitted its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting concluded on January 27, 2026, confirming the approval of these results without any audit qualifications. The company reported zero deviations in the use of proceeds from public or preferential issues. Additionally, no defaults on loans or debt securities were reported for the period.

Board approved unaudited standalone and consolidated financial results for Q3 and 9M ended Dec 31, 2025
Company confirmed zero outstanding defaults on loans and debt securities as of the reporting date
Reported zero deviations or variations in the utilization of proceeds from public or rights issues
The financial results were submitted with an unqualified audit opinion for the period ending December 2025
Board meeting for result approval was conducted between 12:12 P.M. and 01:51 P.M. on January 27, 2026

💡 Investors should examine the detailed Annexure I for specific revenue and margin trends to assess operational performance. The lack of audit qualifications and debt defaults indicates a stable regulatory and credit profile.

Sumitomo Chemical India Submits Quarterly SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 05:03 PM

Sumitomo Chemical India Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The company confirmed that all physical share certificates received for dematerialization were processed, mutilated, and cancelled within the prescribed timelines. The Registrar and Transfer Agent, MUFG Intime India Private Limited, also confirmed that no rematerialization requests were received during this period. This is a standard administrative filing ensuring the integrity of the company's shareholding records.

Compliance certificate issued for the quarter ended December 31, 2025.
Confirmation that dematerialized securities are listed on the BSE and NSE.
Physical certificates were mutilated and cancelled after due verification by the depository participant.
Zero rematerialization requests were received by the company during the quarter.
Filing confirms adherence to SEBI (Depositories and Participants) Regulations, 2018.

💡 No action is required from investors as this is a routine regulatory compliance filing. Investors should continue to monitor the company's operational performance and upcoming financial results.

Sumitomo Chemical Reports Insider Trading Code Violation; Imposes ₹5,000 Penalty

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 02 Jan 2026, 12:27 PM

Sumitomo Chemical India Limited has reported a violation of its Insider Trading Code of Conduct by a Designated Person, Mr. Kaushal Shah, General Manager of the Bhavnagar Plant. The employee pledged 250 shares of the company during November 2025 without obtaining the mandatory pre-clearance from the Compliance Officer. The company has taken corrective action by imposing and recovering a penalty of ₹5,000 from the individual. This amount has been subsequently transferred to the SEBI Investor Protection and Education Fund (IPEF).

Violation involved the unauthorized pledging of 250 shares by a General Manager level employee.
The transaction took place during the week ended November 14, 2025, without required pre-clearance.
A penalty of ₹5,000 was imposed and recovered from the concerned employee on January 2, 2026.
The company confirmed this was the first such instance of violation for the individual.
Penalty proceeds have been transferred to the SEBI Investor Protection and Education Fund.

💡 This is a minor regulatory disclosure with no material impact on the company's financial performance or operations. Investors should view this as a routine compliance update demonstrating the company's internal monitoring systems.

View All SUMICHEM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue for H1 FY26 reached INR 1,986.6 Cr, a 9% YoY increase from INR 1,827.2 Cr. The domestic segment grew 11% YoY, while the export segment declined 4% YoY. Product-wise revenue contribution for H1 FY26 was led by Insecticides at 39%, followed by Herbicides at 26%, Plant Growth Regulators (PGR) at 9%, and Fungicides at 9%.

Geographic Revenue Split

The domestic market is the primary driver, contributing 85% of total revenue in H1 FY26. Exports account for the remaining 15%. Within exports, sales to South America experienced a significant 33% YoY decline during H1 FY26, impacting the overall export growth trajectory.

Profitability Margins

Gross margin for H1 FY26 stood at 40.4%, a slight compression of 47 bps from 40.9% in H1 FY25. Net Profit Margin improved to 17.9% in H1 FY26 from 17.5% in H1 FY25, driven by a 11% growth in Net Profit to INR 355.9 Cr. Operating margins are expected to sustain at 19-20% over the medium term due to high operating leverage.

EBITDA Margin

EBITDA margin for H1 FY26 was 22.0%, down 23 bps from 22.2% in H1 FY25. For Q2 FY26, the EBITDA margin was 23.4%, a decline of 137 bps from 24.8% in Q2 FY25, primarily due to a 6% decline in quarterly revenue to INR 929.8 Cr and higher employee expenses which rose to INR 69.5 Cr.

Capital Expenditure

The company completed an initial capex of INR 120 Cr for five products with a revenue potential of INR 200-250 Cr. A new capex plan of INR 55 Cr has been announced. Annual capex is guided between INR 130 Cr and INR 230 Cr to support the scale-up of recently launched products and manufacturing of proprietary molecules from the parent company.

Credit Rating & Borrowing

The company maintains a debt-free status as of September 30, 2025. Credit ratings highlight a strong financial risk profile with a Total Outside Liabilities to Tangible Networth (TOLTNW) ratio below 0.42 times. Interest costs remain minimal at INR 3.9 Cr for H1 FY26, representing only 0.2% of revenue.

⚙️ Operational Drivers

Raw Materials

The company utilizes chemical intermediates for insecticides, weedicides, and fungicides, with input prices declining in 9M FY25, leading to a 493 bps increase in gross margins to 41.2% during that period.

Capacity Expansion

Current expansion includes a dedicated INR 120 Cr investment for 5 new products and a subsequent INR 55 Cr capex plan. The company is leveraging its parent's chemistry skills to manufacture proprietary products, aiming for a revenue potential of INR 200-250 Cr from the initial 5-product block.

Raw Material Costs

Cost of Goods Sold (COGS) for H1 FY26 was INR 1,183.7 Cr, representing 59.6% of revenue. The company employs rigorous cost optimization in procurement and benefits from declining global input prices to maintain gross margins above 40%.

Manufacturing Efficiency

Operating leverage benefits are expected to sustain margins at 19-20%. Efficiency is driven by tight control on overheads and high fixed cost absorption as export and domestic volumes recover.

Logistics & Distribution

The company focuses on receivable management, with collections in H1 FY26 reaching INR 2,277 Cr, up 14% from INR 1,999 Cr in H1 FY25, ensuring disciplined cash flow despite seasonal challenges.

📈 Strategic Growth

Expected Growth Rate

19-20%

Growth Strategy

Growth will be achieved through the 'SCI 2.0' initiative, focusing on 'Innovate, Nurture, Grow.' This involves launching 5 new products from a INR 120 Cr capex, expanding into specialty high-margin molecules, and leveraging the parent company Sumitomo Chemical Company Ltd's (SCCL) proprietary chemistry and global distribution network.

Products & Services

The company sells crop protection formulations including insecticides, weedicides, fungicides, fumigants, rodenticides, plant growth nutrition products, biorationals, and plant growth regulators.

Brand Portfolio

Sumitomo Chemical India Limited (SCIL).

New Products/Services

Five new products launched via the INR 120 Cr capex are expected to contribute INR 200-250 Cr in annual revenue, representing approximately 6-8% of total annual turnover.

Market Expansion

The company is targeting growth in the domestic market (which grew 11% in H1 FY26) and reinstating export demand by leveraging the brand strength of its Japanese parent, SCCL.

Market Share & Ranking

The company holds a leadership position across several product categories in the domestic crop protection market, though specific market share percentages were not disclosed.

Strategic Alliances

SCIL is a subsidiary of Sumitomo Chemical Company Ltd (SCCL), Japan, providing it exclusive access to proprietary molecules and global R&D capabilities.

🌍 External Factors

Industry Trends

The industry is shifting toward specialty combination products and biorationals. SCIL is positioned to benefit from this trend by leveraging its parent's proprietary chemistry, aiming to maintain operating margins above 20% as demand for crop protection reinstates.

Competitive Landscape

SCIL competes with other domestic and multinational agrochemical players but maintains discipline in order processing and pricing to prioritize profitability over aggressive top-line growth.

Competitive Moat

The company's moat is built on its relationship with SCCL Japan, providing access to proprietary products and a diversified portfolio (insecticides, weedicides, fungicides, PGRs). This advantage is sustainable due to the high entry barriers in specialty chemical manufacturing and patent protections.

Macro Economic Sensitivity

The business is highly sensitive to agricultural cycles; uneven rainfall and low pest pressure can lead to volume declines, as seen in the temporary setbacks during fiscal 2024.

Consumer Behavior

Farmers are increasingly adopting plant growth regulators and biorationals, segments where SCIL is expanding its presence to drive higher margins.

Geopolitical Risks

Macro-economic factors in South America led to a 33% decline in regional sales, highlighting the risk of geographic concentration in specific export markets.

⚖️ Regulatory & Governance

Industry Regulations

The company must comply with cost audit requirements; Messrs GMVP & Associates LLP were appointed as Cost Accountants for FY 2025-26 with a remuneration of INR 0.055 Cr.

Taxation Policy Impact

The effective tax rate for H1 FY26 was approximately 25.6%, with tax expenses of INR 122.6 Cr on a PBT of INR 478.4 Cr.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the seasonality of the agrochemical business and weather-dependent demand, which can cause quarterly revenue fluctuations (e.g., Q2 FY26 revenue fell 6% YoY).

Geographic Concentration Risk

85% of revenue is concentrated in the Indian domestic market, making the company highly dependent on the Indian monsoon and local agricultural economy.

Third Party Dependencies

The company is dependent on its parent, SCCL, for proprietary molecules and technical expertise, which is a core component of its 'SCI 2.0' growth strategy.

Technology Obsolescence Risk

The company mitigates technology risks by focusing on 'Innovate Nurture Grow' and introducing new combination products to replace older generic formulations.

Credit & Counterparty Risk

Receivables quality is high, with trade receivable days at 91 days. Expected credit loss allowance on trade receivables was INR 12.04 Cr for H1 FY26, representing a small fraction of the INR 783.4 Cr receivable base.